Latest Content

Experts across tumor types share their insights on the notable FDA regulatory decisions of 2025.

Phase 1 data demonstrate early safety and efficacy signals with targeting CBP/p300 in patients with solid tumors.

In an OncLive Peer Exchange, experts convened to discuss notable updates in pancreatic cancer from ASCO GI and beyond.

Andrea Necchi, MD, PhD, discusses data from GDFather-NEO evaluating nivolumab plus visugromab in cisplatin-ineligible MIBC.

Raji Shameem, MD, discusses the significance of data from the phase 2 ILUSTRO trial of biomarker-guided triplet therapy in gastric and GEJ adenocarcinoma.

SpotitEarly, an early cancer detection startup that uses AI and trained canines to identify cancer odor signatures in breath samples, today announced a strategic partnership with Fox Chase Cancer Center.

The FDA has approved the Guardant360 CDx as a companion diagnostic for encorafenib in patients with mCRC harboring BRAF V600E-mutations.

The combination of relacorilant and nab-paclitaxel generated an OS benefit vs nab-paclitaxel monotherapy in platinum-resistant ovarian cancer.

The INAVO123 trial is exploring frontline inavolisib plus a CDK4/6 inhibitor and letrozole in PIK3CA-mutant, hormone receptor–positive breast cancer.

Maxwell Lloyd, MD, details the implications of DESTINY-Breast11 and DESTINY-Breast05 data for the use of T-DXd in early-stage HER2-positive breast cancer.

Breast cancer experts convened during an OncLive Scientific Interchange and Workshop to discuss the evolving use of oral SERDs in ER-positive breast cancer.

Shaji Kumar, MD, discusses the mechanism of action of cevostamab, as well as data with a cevostamab-containing triplet in relapsed/refractory myeloma.

Extending endocrine therapy beyond 5e years significantly reduces relapse risk in young women with HR-positive early-stage breast cancer.